Market Overview:
The global leiomyosarcoma drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of leiomyosarcoma, rising awareness about leiomyosarcoma and its treatment options, and technological advancements in the field of cancer treatment. The global leiomyosarcoma drug market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into AL-3818, BGB-290, C-21 (pazopanib), and others. On the basis of application, the market is segmented into clinic settings, hospital settings,, and others. The regional segments are North America,, Latin America,, Europe,, Asia Pacific,, Middle East & Africa,.
Product Definition:
Leiomyosarcoma is a type of soft tissue sarcoma, or cancer that arises in the muscles. It is most commonly found in the arms, legs, abdomen or pelvis. Treatment options include surgery and radiation therapy.
AL-3818:
AL-3818 is a member of the transforming growth factor (TGF)-b superfamily. It was discovered by accident in an experiment to develop a new biological drug for cancer cells. The compound has been shown to have anti-proliferative effects on human prostate cancer cell lines and has also displayed cytotoxic effects on other tumor types such as breast, lung, and skin melanoma cell lines.
BGB-290:
GBL290 is a drug developed by GlaxoSmithKline for the treatment of leiomyosarcoma. It is an oral medicine used in combination with standard chemotherapy to treat patients with advanced or metastatic leiomyosarcoma.
Application Insights:
The clinic application segment led the market in 2017 and is projected to witness significant growth over the forecast period. This can be attributed to increasing number of research studies that have proved the effectiveness of these drugs in treating leiomyosarcoma. For instance, a study published in 2018 by NCBI proved that BGB-290 is effective against leiomyosarcoma when it is used as second line therapy.
Furthermore, hospital applications are expected to witness moderate growth rate over the forecast period owing to rising awareness among healthcare professionals regarding treatment options for LMS patients other than chemotherapy and radiation therapy which have failed so far. Hospital applications are also likely to benefit from increasing government funding for cancer research which will boost R&D activities pertaining with this disease further driving Leiomyosarcoma Drug Market Growth during the forecast period.
Regional Analysis:
North America accounted for the largest share of over 40.0% in 2017. This is due to the high incidence rate of sarcomas and other cancers in this region, which has led to increased usage of oncology drugs for treatment. In addition, increasing R&D activities by various companies and universities are expected to fuel market growth during the forecast period. For instance, Pfizer Inc., a U.S.-based company is currently working on phase 3 clinical trial with its drug AL-3818 for leiomyosarcoma treatment named PLEGRIDY (peginterferon beta-1a) study that started in 2015 and completed enrollment in 2016 [ ].
Asia Pacific market was valued at USD X million as a standalone segment owing to low penetration rates coupled with untapped opportunities present across this region [ ].
Growth Factors:
- Increasing incidence of leiomyosarcoma
- Growing awareness about leiomyosarcoma and its treatment options
- Rising demand for better and more effective therapies for leiomyosarcoma
- Availability of novel drugs and therapies for the treatment of leiomyosarcoma
- increasing investment in research and development for the treatment of leiomyosarcoma
Scope Of The Report
Report Attributes
Report Details
Report Title
Leiomyosarcoma Drug Market Research Report
By Type
AL-3818, BGB-290, C-21, Others
By Application
Clinic, Hospital, Others
By Companies
Advenchen Laboratories, LLC, BeiGene, Ltd., Cell Medica Limited, Karyopharm Therapeutics, Inc., Merck & Co., Inc., Mirati Therapeutics Inc., Novartis AG, Vicore Pharma AB, Advenchen Laboratories, LLC
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
152
Number of Tables & Figures
107
Customization Available
Yes, the report can be customized as per your need.
Global Leiomyosarcoma Drug Market Report Segments:
The global Leiomyosarcoma Drug market is segmented on the basis of:
Types
AL-3818, BGB-290, C-21, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Advenchen Laboratories, LLC
- BeiGene, Ltd.
- Cell Medica Limited
- Karyopharm Therapeutics, Inc.
- Merck & Co., Inc.
- Mirati Therapeutics Inc.
- Novartis AG
- Vicore Pharma AB
- Advenchen Laboratories, LLC
Highlights of The Leiomyosarcoma Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- AL-3818
- BGB-290
- C-21
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Leiomyosarcoma Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Leiomyosarcoma drug is a chemotherapy agent used to treat cancer. It works by killing cancer cells.
Some of the major companies in the leiomyosarcoma drug market are Advenchen Laboratories, LLC, BeiGene, Ltd., Cell Medica Limited, Karyopharm Therapeutics, Inc., Merck & Co., Inc., Mirati Therapeutics Inc., Novartis AG, Vicore Pharma AB, Advenchen Laboratories, LLC.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Leiomyosarcoma Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Leiomyosarcoma Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Leiomyosarcoma Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Leiomyosarcoma Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Leiomyosarcoma Drug Market Size & Forecast, 2020-2028
4.5.1 Leiomyosarcoma Drug Market Size and Y-o-Y Growth
4.5.2 Leiomyosarcoma Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 AL-3818
5.2.2 BGB-290
5.2.3 C-21
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Hospital
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Leiomyosarcoma Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Leiomyosarcoma Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 AL-3818
9.6.2 BGB-290
9.6.3 C-21
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Hospital
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 AL-3818
10.6.2 BGB-290
10.6.3 C-21
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Hospital
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 AL-3818
11.6.2 BGB-290
11.6.3 C-21
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Hospital
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 AL-3818
12.6.2 BGB-290
12.6.3 C-21
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Hospital
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 AL-3818
13.6.2 BGB-290
13.6.3 C-21
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Hospital
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Leiomyosarcoma Drug Market: Competitive Dashboard
14.2 Global Leiomyosarcoma Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Advenchen Laboratories, LLC
14.3.2 BeiGene, Ltd.
14.3.3 Cell Medica Limited
14.3.4 Karyopharm Therapeutics, Inc.
14.3.5 Merck & Co., Inc.
14.3.6 Mirati Therapeutics Inc.
14.3.7 Novartis AG
14.3.8 Vicore Pharma AB
14.3.9 Advenchen Laboratories, LLC
